Table 1 Patient baseline characteristics
Age ± stdev, y | 69±7.5 |
 Range, y | 50-82 |
PSA ± stdev, ng/mL | 7.4±3.2 |
 Range, ng/mL | 2.7-19.5 |
Gleason score 6 | 8 (16%) |
Gleason score 7 | 42 (84%) |
 Primary GS 4 | 19 (38%) |
Cores involved ± stdev (#) | 4.1±2.4 |
 Range | 1-11 |
Cores involved ± stdev (%) | 32±18 |
 Range | 8-80 |
Clinical T stage: | |
 cT1c, % | 86 |
 cT2a, % | 12 |
 cT2b, % | 2 |
NCCN Risk Stage | |
 Low | 8 (16%) |
 Intermediate, favorable | 16 (32%) |
 Intermediate, unfavorable | 26 (52%) |
AUA score ± stdev | 9±7 |
 Range | 0-25 |
SHIM score ± stdev | 13±8.5 |
 Range | 0-26 |
Prostate volume ± stdev (cc) | 63±28 |
 Range | 30-109 |